Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine

Leukemia volume 18, pages 1476–1481 (2004)Cite this article

Abstract

Long-term results of both pretreated and previously untreated patients (pts) with hairy cell leukemia (HCL) using uniformly a single 7-day course of 2-chlorodeoxyadenosine (2-CdA) by continuous infusion are reported. In addition, the probability of obtaining another response with this drug in pts who relapsed after 2-CdA treatment will be addressed. A total of 44 consecutive pts (34 males, 10 females) with a median age of 57 years (range 33–77) at the time of initiation of 2-CdA treatment were analyzed. In all, 11 pts were pretreated with either splenectomy (n=6), interferon α (n=9) or deoxycoformycin (dCF) (n=3) or all procedures in sequence. Two pts treated with dCF did not respond to dCF, but only 2-CdA. The median time to the start of 2-CdA treatment of the 11 pretreated pts was 47 months (mo) (10–160). Out of 44, 43 (98%) achieved complete response (CR) (13 pts with residual disease-RD), one pt reached a good partial response with a single cycle of 2-CdA. Out of 44 pts, 13 had no nonhematologic toxicities at all. Toxicities (WHO grade I–IV) were mainly of grade I and II, in one pt grade IV infectious complication. Bone marrow biopsies were performed at the time of recovery of hematopoiesis, thereafter at 2–3 mo intervals, thereafter at 6 mo, and finally annually in 35 pts. The median follow-up is 8.5 years (0.1–12.2). Disease-free survival from the start of 2-CdA treatment is 36% at 12 years (median 8.4 years), 17/44 pts relapsed. Nine of these pts were treated with 2-CdA again, eight achieved a second CR (median 2.5 yrs), one pt did not respond. Eight of our cohort had a second malignancy before receiving 2-CdA. Six pts died in CR due to the second malignancy. The overall survival at 12 years after the start of 2-CdA treatment is 79%. 2-CdA is a safe and effective treatment of HCL inducing complete remissions in the majority of pts with only a single cycle of 2-CdA, and a paucity of toxicities. Responses are durable and long-lasting. Pts who relapsed following treatment with 2-CdA responded to subsequent retreatment with 2-CdA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Bouroncle BA, Wiseman BK, Doan CA . Leukemic reticuloendotheliosis. Blood 1958; 13: 609–630.

    CAS  PubMed  Google Scholar 

  2. Golomb HM, Catovsky D, Golde DW . Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 1978; 89: 677–682.

    Article  CAS  Google Scholar 

  3. Carson DA, Wasson DB, Beutler E . Antileukemic and immunosuppressive activity of 2-chloro-2-deoxy-adenosine. Proc Natl Acad Sci USA 1984; 81: 2232–2236.

    Article  Google Scholar 

  4. Piro LD, Carrera CJ, Carson DA, Beutler E . Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New Engl J Med 1990; 322: 1117–1121.

    Article  CAS  Google Scholar 

  5. Tallman MS, Hakimian D, Rademaker AW, Zanzig C, Wollins E, Rose E et al. Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood 1996; 88: 1954–1959.

    CAS  PubMed  Google Scholar 

  6. Hoffman MA, Janson D, Rose E, Rai KR . Treatment of hairy-cell leukemia with Cladribine: response, toxicity, and long-term follow-up. JCO 1997; 15: 1138–1142.

    Article  CAS  Google Scholar 

  7. Lauria F, Rondelli D, Zinzani PL, Bocchia M, Marotta G, Salvucci M et al. Remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia 1997; 11: 629–632.

    Article  CAS  Google Scholar 

  8. Saven A, Burian C, Koziol JA, Piro LD . Long-term follow-up of patients with hairy cell leukemia after Cladribine treatment. Blood 1998; 92: 1918–1926.

    CAS  PubMed  Google Scholar 

  9. Jehn U, Bartl R, Dietzfelbinger H, Vehling-Kaiser U, Wolf-Hornung B, Hill W et al. Long-term outcome of hairy cell leukemia (HCL) treated with 2-chlorodeoxyadenosine (2-CdA). Ann Hematol 1999; 78: 139–144.

    Article  CAS  Google Scholar 

  10. Bartl R, Frisch B, Hill W, Burkhardt R, Sommerfeld W, Sund M . Bone marrow histology in hairy cell leukemia: identification of subtypes and their prognostic significance. Am J Clin Pathol 1983; 79: 531–545.

    Article  CAS  Google Scholar 

  11. Anonymous. Consensus resolution. Proposed criteria for evaluation of response to treatment inhairy cell leukemia. 1987; 1: 405–408.

  12. Hakimian D, Tallman MS, Kiley C, Peterson LAC . Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chorodeoxyadenosine for hairy cell leukemia. Blood 1993; 82: 1798–1802.

    CAS  PubMed  Google Scholar 

  13. Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. JAMA 1958; 53: 457–481.

    Google Scholar 

  14. Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M et al. Treatment of hairy cell leukemia with 2-chloro-deoxyadenosine (2-CdA). Blood 1992; 79: 882–887.

    CAS  PubMed  Google Scholar 

  15. Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW et al. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203–2209.

    CAS  PubMed  Google Scholar 

  16. Thaler J, Dietze O, Faber V, Greil R, Denz H, Ho AD et al. Monoclonal antibody B-ly 7: a sensitive marker for detection of minimal residual disease in hairy cell leukemia. Leukemia 1990; 4: 170–175.

    CAS  PubMed  Google Scholar 

  17. Burns GF, Cawley JC, Worman CP . Multiple heavy chain isotypes on the surface of the cells of hairy cell leukemia. Blood 1978; 52: 1132–1136.

    CAS  PubMed  Google Scholar 

  18. Thomas DA, O'Brien S, Bueso-Ramos C, Faderl ST, Keating MJ, Giles FJ et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood 2003; 102: 3906–3911.

    Article  CAS  Google Scholar 

  19. Wheaton S, Tallman MS, Hakimian D, Peterson L . Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood 1996; 87: 1556–1560.

    CAS  PubMed  Google Scholar 

  20. Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H et al. Second cancer risk in hairy cell leukemia: analysis of 350 patients. JCO 1997; 15: 1803–1810.

    Article  CAS  Google Scholar 

  21. Cheson BD, Vena DA, Barett J, Freidlin B . Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. JCO 1999; 17: 2454–2460.

    Article  CAS  Google Scholar 

  22. Federico M, Zinzani PL, Frassoldati A, Vinceti M, Mode A, Annino L et al. Risk of second cancer in patients with hairy cell leukemia: long term follow-up. JCO 2002; 20: 638–646.

    Article  Google Scholar 

  23. Schlaifer D, Rigal-Huguet F, Pris J . Secondary neoplasms in two patients treated with purine analogues. Nouo Rev Fr Hematol 1994; 36: 321 (letter).

    Google Scholar 

  24. Ho AD, Thaler J, Mandelli F, Lauria F, Zittoun R, Willemze R, et al., for the European Organization for the Research and Treatment of Cancer Leukemia Cooperative Group. Response to pentostatin in hairy-cell-leukemia refractory to interferon alpha. J Clin Oncol 1989; 7: 1533–1538.

    Article  CAS  Google Scholar 

  25. Kraut EH, Bouroncle BA, Grever MR . Low-dose deoxycoformycin in the treatment of hairy cell leukemia. Blood 1986; 68: 1119–1122.

    CAS  PubMed  Google Scholar 

  26. Spiers ADS, Moore D, Cassileth PA, Harrington D, Cummings F, Neiman R et al. Remissions in hairy-cell-leukemia with pentostatin. N Engl J Med 1987; 316: 825–830.

    Article  CAS  Google Scholar 

  27. Nieva J, Bethel K, Saven A . Phase 2 study of rituximab in the treatment of cladribin-failed patients with hairy cell leukemia. Blood 2003; 102: 810–813.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany

    U Jehn, R Bartl, T Haferlach & V Heinemann

  2. Technical University, Munich, Germany

    H Dietzfelbinger

Authors
  1. U Jehn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Bartl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Dietzfelbinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V Heinemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U Jehn.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jehn, U., Bartl, R., Dietzfelbinger, H. et al. An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia 18, 1476–1481 (2004). https://doi.org/10.1038/sj.leu.2403418

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403418

Keywords

This article is cited by

Search

Advanced search

Quick links